A black female scientist is pipetting in a laboratory. She's holding a pipette in one hand and a small flask in the other one, while wearing white gloves.
Our Work

Latham & Watkins Advises IDEAYA Biosciences in Public Offering of Common Stock

September 15, 2022
A California-based team advises the biotechnology company in its US$80 million offering.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), announced the pricing of an underwritten public offering of 7,619,048 shares of its common stock at a public offering price of US$10.50 per share, before underwriting discounts and commissions. IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,142,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, are expected to be approximately US$80 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about September 19, 2022, subject to customary closing conditions.

Latham & Watkins LLP represents IDEAYA in the offering with a corporate deal team led by Bay Area partners Mark Roeder and John Williams, with Orange County associates Eric Hanzich, Tiana Baghdikian, and Amy Lutfi and Bay Area associate Natalie Robertson. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Bay Area associate Derek Gumm; on certain intellectual property matters by Bay Area/San Diego partner Chris Hazuka; and on FDA regulatory matters by Washington, D.C. partner John Manthei, San Diego counsel Amy Speros and Bay Area counsel Betty Pang.